Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
- 26 septembre 2024 - 1 mn de lecture
This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.
26 septembre 2024
1 mn de lecture
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
26 septembre 2024
1 mn de lecture
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
26 septembre 2024
1 mn de lecture
Dysport® Adult Upper Limb Spasticity Extension Study
26 septembre 2024
1 mn de lecture
Safety and Efficacy Study of Dysport RU and Glabellar Lines
26 septembre 2024
1 mn de lecture
Dysport® Adult Upper Limb Spasticity
26 septembre 2024
1 mn de lecture
Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical...
26 septembre 2024
1 mn de lecture
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
26 septembre 2024
1 mn de lecture
Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
26 septembre 2024
1 mn de lecture
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
26 septembre 2024
1 mn de lecture